The global diabetic foot ulcer treatment market size was valued at USD 3.6 billion in 2017. It is anticipated to expand at a CAGR of 8.2% over the forecast period. Rising prevalence of diabetes and rapidly growing geriatric population worldwide are among the primary growth stimulants for DFU treatment market. Diabetic foot ulcer is one of the major complications of diabetes mellitus, which forms a major characteristic of diabetic foot.
Healing of wounds is typically an innate mechanism. However, certain metabolic disorders such as diabetes mellitus delays typical pace of wound healing process. Diabetic foot ulcers are most commonly caused by irritated or wounded feet, nerve damage, poor circulation, and high blood sugar (hyperglycemia). Unusual swelling, redness, irritation, and stenches on one or both feet are common initial symptoms of foot ulcer.
DFU treatments, usually include control of blood sugar, removal of dead tissue, wound dressings, and negative pressure therapy. Hyperbaric oxygen therapy may be beneficial but is costly and in some cases, surgery may also improve results. These ulcers are responsible for more than 80.0% of all diabetes-related lower-leg amputations and occur in around 15.0% of diabetic patients.
High cost of ulcer management has been restricting the market from realizing its utmost potential. Many developing and underdeveloped countries demonstrate a lack of healthcare facilities, subsequently limiting market growth. However, adoption of novel therapeutics, improved biologics, and continued prioritization to avoid surgeries and amputations are estimated to offset limitations affecting the growth of the market. Thus, in turn, offering significant opportunities for the market to generate revenue.
On the basis of treatment, the market has been categorized into wound care dressings, biologics, therapy devices, antibiotic medications, and others. Biologics dominated the market, followed by wound care dressings in 2017. They have been divided into growth factors and skin grafts. Biologics are expected to register the highest CAGR during the forecast period.
Wound care dressings have been further segmented into alginate dressings, Hydrofiber dressings, foam dressings, film dressing, hydrocolloid dressings, surgical dressings, and hydrogel dressings. Foam dressings were at the forefront among different types of wound care dressings in 2017.Therapy devices have been bifurcated into negative pressure wound therapy and ultrasound therapy. Spiraling adoption of medical devices for an efficacious, better targeted, and safer treatment of patients is likely to create an upswing in the demand for diabetic foot ulcer therapy devices.
The global DFU treatment market has been categorized into neuropathic, ischemic, and neuro-ischemic ulcers. According to various studies in 1980s, neuropathy was the leading cause responsible for diabetic foot ulcers. However, in the last two decades, there has been an increase in the number of cases of neuro-ischemic or ischemic ulceration in the last two decades.
Neuro-ischemic ulcers are the most prevailing among three types, followed by neuropathic and ischemic, respectively. Neuro-ischemic ulcers accounted for the largest share in the market in 2017. Through the forecast period, they are projected to exhibit the fastest growth, followed by neuropathic ulcers.
North America led the market in 2017. Rising cohort of diabetic patients and adequate healthcare facilities in the region are key factors responsible for the growth of the regional market. Long R&D and approval cycles are required due to capital-intensive nature in North America, which act as a stumbling stone for the growth of the market in the region. However, rising adoption of novel biologics and wound care devices for treatment of these ulcers are contributing to the dominance of North America.
Europe held the second largest share in the market, followed by Asia Pacific. APAC will exhibit the highest CAGR during the forecast period. Increasing prevalence of diabetes and a large geriatric population base in both India and China are supporting the growth of the regional market. This can also be attributed to increased adoption and favorable legislation in developed economies such as Japan and Australia.
Some of the prominent companies operating in the market are ConvaTec, Inc.; Acelity L.P. Inc.; 3M Healthcare; Coloplast A/S; Smith & Nephew Plc.; B. Braun Melsungen AG; Medline Industries, Inc.; Medtronic Plc.; Organogenesis, Inc.; Molnlycke Health Care AB; and BSN Medical GMBH. The players focus on alliances, strategic planning, new treatment planning, and research activities to achieve favorable growth. Currently, Smith & Nephew, Coloplast, CovanTec, Acelity, and 3M Healthcare are leading the market, supported by strong sales of their marketed therapeutic options for the treatment of diabetic foot ulcer.
Potential launches of promising late-stage pipeline products such as FirstString Research’s Granexin gel, ViroMed’s VM 202, and Oneness Biotech’s WH-1 ointment will further drive the market. Few of the other players actively investing in this arena include Centaur Pharmaceuticals Pvt. Ltd.; MediWound Ltd.; Izun Pharmaceuticals Corp.; Issar Pharmaceuticals Pvt. Ltd.; Novalead Pharma Pvt. Ltd.; Karyopharm Therapeutics Inc.; Aurealis Pharma AG; Stratatech Corp.; and ZZ Biotech, LLC.
Report Attribute |
Details |
Market size value in 2020 |
USD 4.6 billion |
Revenue forecast in 2025 |
USD 6.82 billion |
Growth Rate |
CAGR of 8.2% from 2018 to 2025 |
Base year for estimation |
2017 |
Historical data |
2016 - 2017 |
Forecast period |
2018 - 2025 |
Quantitative units |
Revenue in USD million and CAGR from 2018 to 2025 |
Report coverage |
Revenue forecast, company share, competitive landscape, growth factors and trends |
Segments covered |
Treatment, ulcer type, region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; MEA |
Country scope |
U.S.; Canada; U.K.; Germany; Japan; China; India; Brazil; Mexico; South Africa |
Key companies profiled |
ConvaTec, Inc.; Acelity L.P. Inc.; 3M Healthcare; Coloplast A/S; Smith & Nephew Plc.; B. Braun Melsungen AG; Medline Industries, Inc.; Medtronic Plc.; Organogenesis, Inc.; Molnlycke Health Care AB; BSN Medical GMBH |
Customization scope |
Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth at global, regional, and country levels and provides an analysis on industry trends in each of the sub segments from 2016 to 2025. For the purpose of this study, Grand View Research has segmented the global diabetic foot ulcer treatment market report on the basis of treatment, ulcer type, and region:
Treatment Outlook (Revenue, USD Million, 2016 - 2025)
Wound Care Dressings
Alginate Dressings
Hydrofiber Dressings
Foam Dressings
Film Dressing
Hydrocolloid Dressings
Surgical Dressings
Hydrogel Dressings
Biologics
Growth Factors
Skin Grafts
Therapy Devices
Negative Pressure Wound Therapy
Ultrasound Therapy
Antibiotic Medications
Others
Ulcer Type Outlook (Revenue, USD Million; 2016 - 2025)
Neuropathic Ulcers
Ischemic Ulcers
Neuro-ischemic Ulcers
Regional Outlook (Revenue, USD Million; 2016 - 2025)
North America
The U.S.
Canada
Europe
Germany
The U.K.
Asia Pacific
Japan
China
India
Latin America
Brazil
Mexico
MEA
South Africa
This report has a service guarantee. We stand by our report quality.
We are in compliance with GDPR & CCPR norms. All interactions are confidential.
Design an exclusive study to serve your research needs.
Get your queries resolved from an industry expert.
"The quality of research they have done for us has been excellent..."
Multiple therapeutic regimens are being followed across the globe in attempts to come up with a reliable treatment for Covid-19. One line of treatment includes the use of hydroxychloroquine, while a second treatment line focuses to use antiviral drugs used in the disease management of HIV. Both these approaches have surged demand from advanced antivirals and antimalarial drugs. This impacts the drug manufacturers as an off label indication for these drug classes has to be worked upon. At the moment, the WHO has not prescribed any of these approaches, neither they have commented if one is better than the other. The report will account for Covid19 as a key market contributor.